RSS-Feed abonnieren
DOI: 10.1055/s-2006-924424
© J. A. Barth Verlag in Georg Thieme Verlag KG · Stuttgart · New York
Biphasic Insulin Aspart Given Thrice Daily is as Efficacious as a Basal-Bolus Insulin Regimen with Four Daily Injections
A Randomised Open-Label Parallel Group Four Months Comparison in Patients with Type 2 DiabetesPublikationsverlauf
Received: January 3, 2006
First decision: May 3, 2006
Accepted: May 29, 2006
Publikationsdatum:
17. November 2006 (online)
Abstract
Aims: To show that a thrice daily meal-time biphasic insulin aspart (BIAsp) treatment regimen is as efficacious as a 4 times daily basal-bolus regimen with human isophane insulin (NPH) and insulin aspart (IAsp). Methods: A multinational, randomised, open-label parallel-group trial in 394 patients with type 2 diabetes on a once or twice daily insulin regimen. Patients were randomised 1:1 to BIAsp or IAsp+NPH for 16 weeks. The BIAsp group was treated according to individual needs using BMI as a surrogate index of insulin resistance. Subjects administered BIAsp 70 (BMI≤30 kg/m2) or BIAsp 50 (BMI>30 kg/m2) with breakfast and lunch and BIAsp 30 with dinner. The IAsp+NPH group injected IAsp at meals and NPH at bedtime as basal insulin. HbAlc levels after 16 weeks were compared between treatments using a predefined non-inferiority criterion of 0.4%. The incidence of hypoglycaemic episodes and adverse events was evaluated. Results: Mean HbAlc (±SD) decreased from 9.1±0.7% to 7.8±1.0% with both treatments. Glycaemic control provided by BIAsp was non-inferior to that obtained by the IAsp+NPH (intention to treat ITT) population: diff, HbAlc -0.05%; 95% CI (-0.24; 0.14); per protocol (PP) population: diff, HbAlc -0.03%; 95% CI (-0.23; 0.16). Similar improvements in glycaemic control in both groups were confirmed by self-measured 8-point plasma glucose (PG) profiles, average and fasting PG concentrations, and average prandial PG increments. The incidence of adverse events and hypoglycaemic episodes was similar in the two treatment groups. Conclusions: A thrice daily meal-time BIAsp regimen is a suitable alternative to an intensified insulin regimen in people with inadequately controlled type 2 diabetes mellitus, and requires fewer daily injections than a basal-bolus therapy without compromising efficacy and safety.
Key words
Type 2 diabetes - insulin - glycaemic control MS: Biphasic insulin aspart - insulin aspart - premixed insulin analogues - thrice daily insulin regimen - basal-bolus regimen - NovoMix 50 - NovoMix 70 - NovoMix30
References
- 1 American Diabetes Association . Standards of medical care in diabetes. Diabetes Care. 2005; 28 S4-S36
- 2 Boehm BO, Home PD, Behrend C, Kamp NM, Lindholm A. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients. Diabet Med. 2002; 19 393-399
- 3 Boehm BO, Vaz JA, Brondsted L, Home PD. Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes. Eur J Intern Med. 2004; 15 496-502
- 4 Brange J, Volund A. Insulin analogs with improved pharmacokinetic profiles. Adv Drug Deliv Rev. 1999; 35 307-335
- 5 Bruce DG, Chisholm DJ, Storlien LH, Kraegen EW. Physiological importance of deficiency in early prandial insulin secretion in non-insulin-dependent diabetes. Diabetes. 1988; 37 736-744
- 6 Brunner GA, Hirschberger S, Sendlhofer G, Wutte A, Ellmerer M, Ba-lent B, Schaupp L, Krejs GJ, Pieber TR. Post-prandial administration of the insulin analogue insulin aspart in patients with type 1 diabetes mellitus. Diabet Med. 2000; 17 371-375
- 7 Christiansen JS, Vaz JA, Metelko Z, Bogoev M, Dedov I. Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes. Diabetes Obes Metab. 2003; 5 446-454
- 8 Coates PA, Ollerton RL, Luzio SD, Ismail I, Owens DR. A glimpse of the “natural history” of established type 2 (non-insulin dependent) diabetes mellitus from the spectrum of metabolic and hormonal responses to a mixed meal at the time of diagnosis. Diabetes Res Clin Pract. 1994; 26 177-187
- 9 Ejskjaer N, Rasmussen M, Kamp N, Lindholm A, Christiansen JS. Comparison of thrice daily “high” vs. “medium” premixed insulin aspart with respect to evening and overnight glycaemic control in patients with type 2 diabetes. Diabetes Obes Metab. 2003; 5 438-445
- 10 Heller SR, Colagiuri S, Vaaler S, Wolffenbuttel BH, Koelendorf K, Fri-berg HH, Windfeld K, Lindholm A. Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with type 1 diabetes. Diabet Med. 2004; 21 769-775
- 11 Home PD. Insulin aspart vs. human insulin in the management of long-term blood glucose control in type 1 diabetes mellitus: a randomized controlled trial. Diabetic Medicine. 2000; 17 762
- 12 International Conference on Harmonisation (ICH) . Topic E 6. Harmonised Tripartite Guideline for Good Clinical Practice. Step 5, Consolidated Guideline. 1-5 1996;
- 13 Jain R, Allen E, Wahl T, Wahlen J, Bressler P, Deng L, Garber A. Efficacy of biphasic insulin aspart 70/30 in patients with T2DM not achieving glycemic targets on OADs with/without basal insulin therapy. Abstract submitted for presentation at American Diabetes Association (ADA) 10-14 June San Diego, California 2005
- 14 Jain R, Wahl T, Wahlen J, Bressler P, Hu P, Allen E. Patients with type 2 diabetes can achieve A1C targets with once-daily biphasic insulin aspart 70/30 before supper. Diabetes. 2004; 53 A130
- 15 Kann P, Toft A. Twice daily biphasic insulin aspart 30 plus metformin compared with once-daily insulin glargine in combination with gli-mepiride in type 2 diabetes. Diabetic Medicine. 2006; 23 10
- 16 Kapitza C, Rave K, Ostrowski K, Heise T, Heinemann L. Reduced postprandial glycaemic excursion with biphasic insulin aspart 30 injected immediately before a meal. Diabet Med. 2004; 21 500-501
- 17 Kilo C, Mezitis N, Jain R, Mersey J, McGill J, Raskin P. Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin. J Diabetes Complications. 2003; 17 307-313
- 18 Liebl A. et al . Poster presented at the American Diabetes Association (ADA). 2006; , Abstract number 950876.
- 19 Lindholm A, McEwen J, Riis AP. Improved postprandial glycemic control with insulin aspart. A randomized double-blind cross-over trial in type 1 diabetes. Diabetes care. 1999; 22 801-805
- 20 McNally PG, Nelson G, Pitsch M. Patients with type 2 diabetes mellitus have lower rates of nocturnal hypoglycaemia on biphasic insulin aspart (BIAsp30) than on biphasic human insulin-30 (BHI30): data from the REACH study. Diabetologia. 2004; 47 A327
- 21 Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P, Bode B, Garber A. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005; 28 260-265
- 22 Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care. 2000; 23 583-588
- 23 Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003; 26 3080-3086
- 24 Rosenfalck AM, Thorsby P, Kjems L, Birkeland K, Dejgaard A, Hanssen KF, Madsbad S. Improved postprandial glycaemic control with insulin aspart in type 2 diabetic patients treated with insulin. Acta Diabetol. 2000; 37 41-46
- 25 Thivolet C, Clements M, Ligthelm RJ, Tits J, Kinsley B, Friberg HH. High-mix regimen of biphasic insulin aspart improves glycaemic control in patients with diabetes. Diabetologia. 2002; 45 A254
- 26 Warren ML, Conway MJ, Klaff LJ, Rosenstock J, Allen E. Postprandial versus preprandial dosing of biphasic insulin aspart in elderly type 2 diabetes patients. Diabetes Res Clin Pract. 2004; 66 23-29
- 27 Weyer C, Heise T, Heinemann L. Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture. Diabetes Care. 1997; 20 1612-1614
- 28 World Medical Association Declaration of Helsinki . Ethical principles for medical research involving human subjects. JAMA. 2000; 284 3043-3045
Correspondence
Dr. Robert J. Ligthelm
Havenziekenhuis·Afd. Interne Geneeskunde
Haringvliet 2
3011 TD Rotterdam
The Netherlands
Telefon: +3/11/04 04 33 00
Fax: +3/11/04 14 51 38
eMail: rjligthelm@cistron.nl